Skip Ribbon Commands
Skip to main content

Motility Monitoring

Indications & Risks


  • The SmartPill motility monitoring system measures whole gut and regional gut (stomach, small bowel and colon) transit times.  Measurements of gastrointestinal tract transit times are used for evaluating motility disorders
  •  Gastric transit time (or gastric emptying time, GET) is indicated for the evaluation of patients with suspected gastroparesis.  Delayed gastric emptying is suggested in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia
  •  Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation and used to aid in differentiating slow and normal transit constipation.  Combined small and large bowel transit time (SLBTT) is used as a surrogate measure of colonic transit in patients with chronic constipation when colonic transit time alone cannot be determined
  • The system measures pH, pressure and temperature throughout the entire GI tract.  Pressure contraction data from the antrum and duodenum can be used to calculate motility indices
  •  Not for use in pediatric patients (children under the age of 18 years)


  • A history of gastric bezoars
  • Swallowing disorders
  • Suspected or known strictures, fistulas or physiological/mechanical GI obstruction
  • History of gastrointestinal surgery within the past three months
  • Severe dysphagia to food or pills
  • Crohn’s disease or diverticulitis
  • Cardiac pacemakers or other implanted electromedical devices

Procedure Risks

The risks of SmartPill® motility monitoring include capsule retention and aspiration. Before administering SmartPill, physicians should rule out physiological and/or mechanical GI obstruction as a cause of patient symptoms.
Significant data dropout can occur in severely obese patients (>40 BMI). Physicians should not perform an MRI until capsule passage is confirmed by physician review of the MotiliGI® graph or an x-ray of the kidneys, ureter and bladder (KUB). If a SmartPill capsule is in the body during an MRI test, there is a risk of damage to the GI tract.
This information should not be used as a substitute for medical advice concerning specific diagnosis and treatment.